Hideyuki Hayashi1, Takashi Kohno, Hideki Ueno, Nobuyoshi Hiraoka, Shunsuke Kondo, Motonobu Saito, Yoko Shimada, Hitoshi Ichikawa, Mamoru Kato, Tatsuhiro Shibata, Chigusa Morizane, Yasunari Sakamoto, Kazuaki Shimada, Yoshito Komatsu, Naoya Sakamoto, Takuji Okusaka. 1. From the *Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo; †Division of Genome Biology, National Cancer Center Research Institute, Tokyo; ‡Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo; §Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo; ∥Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo; Divisions of ¶Genetics and #Cancer Genomics, National Cancer Center Research Institute, Tokyo; and **Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Abstract
OBJECTIVES: KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcinogenesis. We examined somatic mutations in 50 cancer-related genes, including the four above-mentioned driver genes, to identify genomic biomarkers for predicting the outcome of patients with pancreatic cancer. METHODS: Genomic DNA was extracted from fresh-frozen specimens obtained from 100 patients with pancreatic cancer who had undergone a pancreatectomy with curative intent. The mutation profile was obtained using a single targeted deep sequencing assay performed with a next-generation sequencer, and the associations with clinicopathological factors were analyzed. RESULTS: Mutations in the KRAS, CDKN2A, TP53, and SMAD4 genes were detected in 96% (96/100), 42% (42/100), 13% (13/100), and 7% (7/100) of all patients, respectively. Among the 71 patients who underwent a radical operation followed by adjuvant chemotherapy, patients with fewer mutations among the four driver genes tended to have a better outcome. A multivariate analysis using the Cox proportional hazard model showed that the presence of 0 to 2 mutated driver genes was an independent predictor of a better overall survival (hazard ratio for death, 0.20; P = 0.0040). CONCLUSIONS: The number of mutated driver genes assessed using a targeted deep sequencing assay was a promising prognostic biomarker for pancreatic cancer.
OBJECTIVES:KRAS, CDKN2A, TP53, and SMAD4 have been recognized as major driver genes in pancreatic carcinogenesis. We examined somatic mutations in 50 cancer-related genes, including the four above-mentioned driver genes, to identify genomic biomarkers for predicting the outcome of patients with pancreatic cancer. METHODS: Genomic DNA was extracted from fresh-frozen specimens obtained from 100 patients with pancreatic cancer who had undergone a pancreatectomy with curative intent. The mutation profile was obtained using a single targeted deep sequencing assay performed with a next-generation sequencer, and the associations with clinicopathological factors were analyzed. RESULTS: Mutations in the KRAS, CDKN2A, TP53, and SMAD4 genes were detected in 96% (96/100), 42% (42/100), 13% (13/100), and 7% (7/100) of all patients, respectively. Among the 71 patients who underwent a radical operation followed by adjuvant chemotherapy, patients with fewer mutations among the four driver genes tended to have a better outcome. A multivariate analysis using the Cox proportional hazard model showed that the presence of 0 to 2 mutated driver genes was an independent predictor of a better overall survival (hazard ratio for death, 0.20; P = 0.0040). CONCLUSIONS: The number of mutated driver genes assessed using a targeted deep sequencing assay was a promising prognostic biomarker for pancreatic cancer.
Authors: Caitlin A McIntyre; Sharon A Lawrence; Allison L Richards; Joanne F Chou; Winston Wong; Marinela Capanu; Michael F Berger; Mark T A Donoghue; Kenneth H Yu; Anna M Varghese; David P Kelsen; Wungki Park; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Christine A Iacobuzio-Donahue; Peter J Allen; Eileen M O'Reilly Journal: Cancer Date: 2020-06-23 Impact factor: 6.860
Authors: Sami Shoucair; Joseph R Habib; Ning Pu; Benedict Kinny-Köster; A Floortje van Ooston; Ammar A Javed; Kelly J Lafaro; Jin He; Christopher L Wolfgang; Jun Yu Journal: Ann Surg Oncol Date: 2021-11-18 Impact factor: 5.344
Authors: Yixuan Ma; Sina Sender; Anett Sekora; Weibo Kong; Peter Bauer; Najim Ameziane; Susann Krake; Mandy Radefeldt; Ruslan Al-Ali; Frank Ulrich Weiss; Markus M Lerch; Alisha Parveen; Dietmar Zechner; Christian Junghanss; Hugo Murua Escobar Journal: Int J Mol Sci Date: 2022-04-16 Impact factor: 6.208
Authors: Hossein Taghizadeh; Leonhard Müllauer; Robert M Mader; Martin Schindl; Gerald W Prager Journal: Ther Adv Med Oncol Date: 2020-07-10 Impact factor: 8.168
Authors: Danielle C Glassman; Randze L Palmaira; Christina M Covington; Avni M Desai; Geoffrey Y Ku; Jia Li; James J Harding; Anna M Varghese; Eileen M O'Reilly; Kenneth H Yu Journal: BMC Cancer Date: 2018-06-27 Impact factor: 4.430